Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of “Buy” from Analysts

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has been given a consensus recommendation of “Buy” by the fifteen research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $111.4615.

A number of analysts have recently weighed in on SLNO shares. Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group set a $125.00 price target on Soleno Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 7th. Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $106.00 target price (down from $123.00) on shares of Soleno Therapeutics in a research note on Wednesday, November 5th.

Institutional Investors Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLNO. CIBC Bancorp USA Inc. acquired a new position in shares of Soleno Therapeutics during the third quarter worth $301,000. Danske Bank A S acquired a new stake in Soleno Therapeutics in the third quarter valued at $27,000. PharVision Advisers LLC acquired a new stake in Soleno Therapeutics in the third quarter valued at $288,000. Samlyn Capital LLC lifted its holdings in Soleno Therapeutics by 94.1% during the 3rd quarter. Samlyn Capital LLC now owns 466,175 shares of the company’s stock worth $31,513,000 after buying an additional 226,048 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its position in shares of Soleno Therapeutics by 45.7% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,191,123 shares of the company’s stock worth $80,520,000 after acquiring an additional 373,623 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Soleno Therapeutics Stock Down 2.5%

Shares of SLNO opened at $51.37 on Friday. The company’s 50-day simple moving average is $57.23 and its 200-day simple moving average is $69.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.88 and a current ratio of 16.08. Soleno Therapeutics has a 1 year low of $41.50 and a 1 year high of $90.32. The stock has a market capitalization of $2.76 billion, a PE ratio of -27.92 and a beta of -3.15.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.39. The business had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million. Analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.